+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Influenza viruses and cross-reactivity in healthy adults Humoral and cellular immunity induced by seasonal 27/28 influenza vaccination against vaccine antigens and 29 AH1N1 pandemic influenza virus

Influenza viruses and cross-reactivity in healthy adults Humoral and cellular immunity induced by seasonal 27/28 influenza vaccination against vaccine antigens and 29 AH1N1 pandemic influenza virus

We analyzed humoral and cellular immune responses against vaccine antigens and the new A(H1N1) virus in healthy adults before and after immunization with the 27/28 commercially available trivalent subunit MF59-adjuvanted influenza vaccine during the Fall 27, prior to the emergence of the new virus. Antibody titers were significantly boosted only against the three vaccine antigens. Seasonal vaccination boosted pre-existing cellular responses upon stimulation of peripheral blood mononuclear cells not only with the homologous three vaccine antigens, but also with the heterologous new 29 A(H1N1) and with a highly conserved peptide present in the stalk region of hemagglutinin (HA). These results show that cross-reactive cell responses against the new virus were present before the circulation of the virus and were boosted by seasonal vaccination. The cross-reactivity of cellular responses might, at least in part, explain the low pathogenicity of the new pandemic virus. The finding of cellular immunity, that can be increased by seasonal vaccination, against the conserved HA peptide, underline the potential use, in human vaccines, of conserved peptides of the stalk region of HA characterized by broad immunogenicity in experimental systems.Humoral and cellular immune responses after seasonal 27/28 influenza vaccination. Significant homologous humoral and cellular immunity induced against vaccine antigens. Cross-reactive cellular responses, but not humoral against new pandemic virus..

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 036312935

Download citation: RISBibTeXText

Related references

Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine 30(9): 1617-1623, 2012

Seasonal influenza vaccination coverage in France during two influenza seasons 27 and 28 and during a context of pandemic influenza AH1N1 in 29. 2011

CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. European Journal of Immunology 42(7): 1755-1766, 2012

Survey of distribution of seasonal influenza vaccine doses in 201 countries (2004-2015): The 2003 World Health Assembly resolution on seasonal influenza vaccination coverage and the 2009 influenza pandemic have had very little impact on improving influenza control and pandemic preparedness. Vaccine 35(36): 4681-4686, 2017

Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. Journal of Virology 86(10): 5953-5958, 2012

Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial. Plos one 8(3): E59674, 2013

Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. Journal of General Virology 94(Pt 3): 583-592, 2013

Long-lasting immunogenicity and safety of a 29 pandemic influenza AH1N1 MF59-adjuvanted vaccine when co-administered with a 29–21 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus. 2011

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine. Pediatric Infectious Disease Journal 31(6): E86-E91, 2012

A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults. Human Vaccines and Immunotherapeutics 10(1): 92-99, 2014

Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. Journal of General Virology 92(Pt 10): 2339-2349, 2011

Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clinical and Vaccine Immunology 16(4): 437-443, 2009

Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses. Journal of Infectious Diseases 213(3): 403-406, 2016

Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. Journal of Infectious Diseases 202(7): 1011-1020, 2010

Ostrich produce cross-reactive neutralization antibodies against pandemic influenza virus A/H1N1 following immunization with a seasonal influenza vaccine. Experimental and Therapeutic Medicine 2(1): 41-45, 2011